Home Labcorp Drug Development Sitemap

Labcorp Drug Development Sitemap

Sitemap List

Drug Development

Preclinical Oncology CRO | Labcorp Drug Development

Model & tech spotlights

4T1-luc2: An orthotopic mammary cancer odel to support novel immuno-oncology drug discovery

5TGM1-luc – A syngeneic murine model for multiple myeloma

786-O (pMMP-LucNeo) – A model for renal cell carcinoma

A20: Modeling B cell lymphoma in mice

Absolute counts by flow cytometry — maximize the accuracy of your immunophenotypic data interpretation

A deeper dive into the tumor-infiltrating T Cell immunophenotype

B16-F10: a murine melanoma model

5TGM1-luc – A syngeneic murine model for multiple myeloma

A549 – A model for non-small cell lung cancer

Predictive Oncology® Reconstructed Bone (r-Bone)

Syngeneic model for preclinical evaluation of ovarian cancer

Comprehensive dendritic cell analysis by flow cytometry using the new CompDC™ panel

Modeling human acute lymphoblastic leukemia (ALL) – using the NALM6-Luc-mCh-Puro model for the development of CAR T cell therapies

C1498: A murine model for acute myelogenous leukemia (AML)

Colo-205 as a translational imaging model for colorectal cancer

Pan02: A murine model of pancreatic cancer

Hepa 1-6: A murine model of hepatocellular carcinoma

CT26: Murine colon carcinoma

Modeling liver cancer with syngeneic hepa 1-6: an update

Models for non-small cell lung carcinoma

MM.1S: A model for multiple myeloma

ID8 syngeneic ovarian cancer model response to checkpoint inhibitors

Targeting B Cell malignancies? Raji-Luc is a model to test CD19-directed CAR-T cells and other novel approaches

PyMT – a transplantable murine model of breast cancer

Update on the preclinical use of hPBMC for immuno-oncology modeling

Focal radiation in the murine 4T1-luc2 mammary cancer model

Subcutaneous and systemic preclinical modeling of A20 murine B cell lymphoma

Pan02 – pancreatic ductal adenocarcinoma model characterized for immuno-oncology applications

Measuring Tumor Antigen-Specific Immunity Through ELISpot and FluoroSpot

Functional analysis of tumor infiltrating lymphocytes by flow cytometry using the cytokine/cytotoxicity™ panel

MDA-MB-231-luc-D3H2LN: A valuable model for triple-negative breast cancer research

MV(4;11): A model of human AML (acute myeloid leukemia)

Phospho-protein detection in solid tumors using phospho-flow cytometry

MC38: An immunoresponsive murine tumor model

Prostate cancer modeling with PC-3: One model, four applications

MB49 – a bladder cancer murine tumor model

E0771 syngeneic breast cancer model

EMT-6 syngeneic breast tumor model – a powerful tool for immuno-oncology studies

HCC70: A model of triple negative breast cancer

HT-29 as a preclinical model for colorectal cancer

Models for pancreatic cancer

ID8: A syngeneic mouse model for testing ovarian cancer immunotherapies

C1498-Luc-mCherry: A syngeneic acute myeloid leukemia (AML) model

GL261: Syngeneic murine glioma model

Models for non-small cell lung carcinoma - part 2

LL/2: an immunosuppressive murine tumor model

NCI-H2228 – usage of DCE MRI in a non-small cell lung cancer orthotopic brain metastatis model

BT-474 Human ductal breast carcinoma: New life for an old model

GL261-luc: A model for immunotherapy and radiation therapy

PC-3M-Luc-C6 – a model for prostate carcinoma

Modeling immuno-oncology in a humanized mouse

Multiplex IHC for patterns of protein expression, co-expression, and spatial relationships

NCI-1975-Luc and PC-9-Luc: two models for evaluating brain metastases from non-small cell lung cancer It is missing the “H” NCI-H1975-Luc and PC-9-Luc: two models for evaluating brain metastases from non-small cell lung cancer

Preclinical oncology imaging capabilities and expertise

Analysis of the tumor-infiltrating myeloid subsets with high dimensional flow cytometry using the Expanded CompMyeloid™ panel

Measuring human cytokines in mouse samples in the discovery setting: Understanding immunoassay technology and managing the risk

Combination therapies in oncology: The future of CAR T cell therapy for solid tumors

Determining preclinical CAR T-cell persistence by flow cytometry

Cloudman S91 – a responsive syngeneic melanoma model

Labcorp chimeric antigen receptor (CAR) T cell generation service

Luciferase-labeled cell lines: a valuable tool for oncology studies

Clinical standards of care in preclinical models of multiple myeloma

Pan02-Luc: An orthotopic model of pancreatic cancer

CT26-Luc: An orthotopic murine model of colon cancer: implications for immuno-oncology studies

EMT6-Luc: In vivo monitoring of metastatic development and treatment efficacy

Bioluminescence imaging: In vivo monitoring of tumor development, disease dissemination and treatment efficacy

Labcorp Drug Development Preclinical Oncology Biosafety Level 2 Capabilities and Ongoing Expansion

RM-1: A Syngeneic Murine Prostate Gland Carcinoma Model

Raising the Bar in Preclinical Oncology

The nCounter® IO 360™ panel and flow cytometry combine transcriptome and immune subset immunophenotypic profiles to offer comprehensive analysis of tumor immunotherapy

Plate-based 3D culture assays that mimic the tumor microenvironment and predict in vivo responses

Exploring orthotopic glioblastoma models to treat tumors and strengthen immune responses in the brain

E.G7-OVA: Murine Thymic Lymphoma

NHDF (normal human dermal fibroblasts)

OVCAR-5: Human Ovarian Carcinoma

NCI-H3122: Human Lung Adenocarcinoma

NCI-H929-Luc-mCh-Puro Human Multiple Myeloma

Pan02: Murine pancreatic ductal adenocarcinoma

OVCAR-8: Human Ovarian Carcinoma

NCI-H460 Human Lung Carcinoma

U-87 MG-Luc: Human glioblastoma

SW-480: Human Colon Carcinoma

SW-620: Human Colon Carcinoma

SU-DHL-10 Human Large Cell Lymphoma

NCI-N87: Human Gastric Carcinoma

Reh (pMMP-Luc-Neo) Human B Cell (Acute Lymphocytic) Leukemia

Raji-luc: Human B-Cell Lymphoma

Ramos: Human B-cell Lymphoma

U-251-luc-mCh-Puro: Human Glioblastoma

SNU-5 Human Gastric Carcinoma

RIF-1: Mouse Sarcoma

SJSA-1 Human Osteosarcoma

PC-3M-Luc-C6 (SC-axilla)

PC-3M-Luc-C6 (Peritibial)

PC-3M-Luc-C6 (Orthotopic)

PC-3M-Luc-C6 (Intracardiac)

PANC-1: Human Pancreatic Carcinoma

SK-OV-3-LUC-D3 (INTRAPERITONEAL)

SK-OV-3 (SUBCUTANEOUS)

OVCAR-8-Luc-mCh-Puro

YUMM1.7: Murine Melanoma

ZR-75-1: Human Mammary Carcinoma (w/estradiol)

NCI-H23: Human Non-Small Cell Lung Carcinoma

NCI-H1975 Human Non-Small Cell Lung Carcinoma

NCI-H1703-LUC-MCH-PURO

NALM6-Luc: Adult B Acute Lymphoblastic Leukemia

MV-4-11-Luc-mCh-Puro: Human Acute Meylogenous Leukemia

MOLT-4-LUC-MCH-PURO

MM.1S (pMMP-Luc-Neo): Human Plasma Cell Myeloma

MIA PaCa-2: Human Pancreatic Ductal Adenocarcinoma

MDA-MB-231-LUC-D3H3

MDA-MB-231-Luc-D3H2LN: Human Mammary Carcinoma

MDA-MB-231-LUC-D3H2

MDA-MB-231-LUC-D3H1

MDA-MB-231-2LMP

MDA-MB-231: Human Mammary Carcinoma

MCF7-LUC-MCH-PURO

MC38: Murine Colon Adenocarcinoma

MB49-LUC-MCH-PURO

MB 49: Murine Bladder Cell Carcinoma

LOX-IMVI: Human Melanoma

LNCAP CLONE FGC

LN-827 (PMMP-LucNeo): Human Glioma

Lewis Lung: Mouse Lung Carcinoma

KP4: Human Pancreatic Ductal Carcinoma

Kg-1-Luc-mCh-Puro: Human Leukemia (AML)

Kasumi-3-Luc-mCh-Puro: Human Leukemia (AML)

Kasumi-1 Human Acute Myeloblastic Leukemia

Jurkat-Clone E6-1

Jurkat: Human Lymphoblastic Leukemia

JJN-3-LUC-G418R

J558-Luc-mCh-Puro

IGROV1: Human Ovarian Carcinoma

ID8-Luc: Murine Ovarian Carcinoma

HT-29: Human Colon Carcinoma

HEPA 1-6-LUC-MCH-PURO

Hep-55.1C-Luc-Mch-Puro

Hep 3B2.1-7: Human Hepatocellular Carcinoma (HCC)

Hel 92.1.7-Luc-Neo

HEKN (Human Epithelial Keratinocytes)

Hek 293-Luc-mCh-Puro

HCT-116: Human Colon Carcinoma

HCC827-LUC-MCH-PURO

HCC70: Human Triple Negative Mammary Carcinoma

GLI36-DSRED-R-LUC (RESCUED)

GL261-Luc2: Mouse Glioma

GIST-T1: Human Gastrointestinal Stromal Tumor

FaDu: Human Pharyngeal Squamous Cell Carcinoma

EMT-6 Murine Mammary Carcinoma

E0771: Murine Mammary Carcinoma

DU 145: Human Prostate Carcinoma

DND-41-LUC-MCH-PURO

DLD-1: Human Colon Carcinoma

Daudi-luc-mCh-Puro: Human B-Cell Lymphoma

D54-Luc: Human Glioma

CT26.WT: Murine Colon Carcinoma

COLO 829: Human Melanoma

COLO 205-LUC #2

COLO 205: Human Colon Carcinoma

Calu-6: Human Lung Adenocarcinoma

CAL 27: Human Tongue Squamous Cell Carcinoma

C51: Mouse Colon Carcinoma

C26: Mouse Colon Carcinoma

C1498-Luc: Murine Leukemia

Bx-PC-3: Human Pancreatic Carcinoma

BT-474: Human Mammary Invasive Ductal Carcinoma

BNL 1ME A.7R.1-LUC-MCH-PURO

B16-F10-Luc2: Murine Melanoma

B16-F10: Murine Melanoma

ACHN Human Renal Carcinoma

AB1-LUC-MCH-PURO

A549: Human Lung Carcinoma

A375: Human Melanoma

A20 Murine B Cell Lymphoma

A-498 Human Renal Carcinoma

5TGM1-Luc: Murine Multiple Myeloma

4T1-LUC2: Mouse Mammary Carcinoma

NIH:OVCAR-3-LUC-MCH-PURO

OCI-LY19-LUC-NEO

OCI-LY3-LUC-MCH-PURO

OCI-LY7-LUC-MCH-PURO (RESCUED)

OCI-LY7-LUC-NEO

OCM-1-LUC-MCH-PURO

OVCAR-5-LUC-MCH-PURO

PAN02.TD1-LUC-MCH-PURO

Syngeneic Cancer Cell Lines and Growth Curves

OVCAR-3 (PMMP-LUC-NEO): Human ovarian carcinoma – Intra-bursa

OVCAR-3 (PMMP-LUC-NEO): Human ovarian carcinoma – IP

NCI-H1299-Luc: Human Large Cell Lung Carcinoma

SK-MEL-28-Luc-mCh-Puro

SU-DHL-10-LN-HIGH

SU-DHL-4-LUC-MCH-PURO

SU-DHL-6-LUC-MCH-PURO

Subcutaneous Models

Orthotopic Models

Metastasis Models

Disseminated Models

Immunohistochemistry

Protein expression

DNA/RNA expression

Droplet Digital PCR (ddPCR)

Cell & tissue processing

3D Cell Culture

Blood/plasma analysis

A comparative evaluation of immunotherapy responses in murine colon carcinoma

Anti-mCTLA-4 treatment results in early and late immune response effects in a murine model of colorectal carcinoma

Characterization of proliferation in multiple lymphocyte subsets in the CT26 murine colon carcinoma model by multi-color flow cytometry

Combination of a glycomimetic antagonist to E-selectin and CXCR4, GMI-1359, with an anti-PD-L1 antibody attenuates regulatory T Cell infiltration and accelerates time to complete response in the murine CT26 tumor model

Combination of rapamycin with immune checkpoint blockade in a syngeneic breast carcinoma model

Combined dynamic 18F-FDG PET imaging and DCE prediction of treatment response in an orthotopic model of glioblastoma multiforme

Combined focal radiation and anti-mCTLA-4 antibody therapy modulates myeloid subset phospho-stat3 levels in the 4T1 tumor microenvironment, and results in tumor growth inhibition

Comprehensive 10-color flow cytometry analysis of the neuroblastoma intratumoral immune response using the murine syngeneic Neuro-2a tumor model

Evaluation of the immune response following treatment with anti‐CTLA‐4 antibody, radiation therapy or the combination in a murine model of breast cancer

Evaluation of immunomodulatory agents in classically immunologically “cold” cancers using syngeneic mouse models of breast and ovarian cancer

Focal radiation enhances paclitaxel therapy in a mouse model of triple negative breast cancer

High-throughput analysis of MAPK and JAK-STAT signaling in CT26 tumors using a combination of immunophenotyping and phospho-flow cytometry

ID8-Luc syngeneic ovarian cancer model for preclinical evaluation of immunomodulatory molecules

Image-guided focal irradiation in syngeneic preclinical oncology mouse models

Imaging the future | Published in the European Biopharmaceutical Review

In-depth myeloid cell characterization in the murine syngeneic CT.26 colon carcinoma model by 10-color flow cytometry

Preclinical assessment of anti-tumor activity and immune response in syngeneic tumor models

Preclinical models of multiple myeloma

Preclinical response of murine syngeneic tumor models to immune checkpoint inhibitor antibodies

Preclinical use of focal radiation and immune checkpoint blockade to improve therapeutic response in an immunologically cold tumor

Radiation enhances anti-tumor activity of checkpoint blockade in syngeneic tumor models

Radiation response in preclinical orthotopic models of brain cancer

Sensitivity of syngeneic tumor models to focal radiation

Systemic and subcutaneous modeling of A20 murine B cell lymphoma in mice: A comparative assessment

TIGIT directed human antibody modulates T-regulatory and effector cell function

Fast Track Discovery

Clinical trials

Top 5 Models for Immuno-oncology Studies

Top 5 Design Considerations for Preclinical Immuno-oncology

In Vitro Metabolism

Enzyme Induction

Enzyme Inhibition

Metabolic Stability

Metabolism Protein Binding Studies & Services | Covance Preclinical

Reaction Phenotyping

Transporters & DDIs

In Vivo Metabolism

Modeling & In Silico

Compartmental PK

PK / PD Modeling

QSP / SP Modeling

Custom Antibody Reagents

Reagent Portfolio Management Solution

Critical Antibody Reagents

Polyclonal Antibody Services

Monoclonal Antibody Production

Antibody Reagent Scientific Spotlights

Core Lead Optimization Toxicology Services

Safety Assessment

Comprehensive Leukocyte Quantitation

RD Oncology Cell Line Assays

Nonclinical Imaging

Computed Tomography

Bioluminescence

Positron Emission

Rabies Vaccine and Antiviral Testing Services

Toxicologic Pathology CRO Services

Anatomic pathology

Clinical pathology

Specialty pathology

Electron microscopy

Immunohistochemistry

Tissue cross reactivity

Digital pathology

Lifecycle development

Project management

Administration routes

Clinical Development

Clinical Testing & Labs

Functional Service Provider (FSPx)

Early Phase Development

IND & CTA Enabling Studies

Nonclinical Locations

Educational Resources

Peri-Approval & Commercialization

Data and Technology

Artificial Intelligence

Scientific spotlights

Pharma Companies

Biopharmaceutical

Become an Investigator

Accreditations and Certifications

Current Investigator Resources

Courier Numbers

Privacy Statement: Institution

Privacy Statement: Investigator

Privacy Statement: Study Staff

Videos: Packing & Shipping

Videos: Sample Collection

Life science investors

Articles & Research

Knowledge Library

Secure PDF Viewer

RD Preference Center

RD Subscription Center

Thanks for Subscribing!

Why Animal Research

Impact on Results

Beliefs in Action

Corporate Responsibility

Vaccine Development

Clinical Trial Connect

Trials & Recruitment

Clinical Testing & Labs

Commercialization

Product Testing

Design Better Studies

Xcellerate Protocol Design Tool

Xcellerate Patient Intelligence

Improve Study Recruitment

Xcellerate Recruitment Analysis & Forecasting

Xcellerate Site List Tool

Xcellerate Spatial Cluster Analysis

Reduce Study Risk

Xcellerate Risk Assessment & Categorization Tool

Xcellerate Risk & Issue Management

Xcellerate Risk Review

Gain Operational Insights

Xcellerate Action Alerts

Xcellerate CRA Dashboard

Xcellerate Study Dashboard

Xcellerate Portfolio Dashboard

Ensure Data Quality

Xcellerate Medical Review

Xcellerate Statistical Review

Xcellerate Data Review

Access Central Lab Information

Xcellerate Lab Sponsor Portal

Xcellerate LabLink+

Xcellerate Lab Investigator Portal

Empower Your Data

Xcellerate Clinical Data Warehouse

Xcellerate Operational Data Warehouse

Maximize Product Access

Xcellerate Patient Access Toolkit

Xcellerate Access Intelligence Dashboard (XAID)

Transform Patient Safety

Xcellerate Case Management

Xcellerate Safety Reporting

Home Contact Us Preference Center Privacy Locations Terms of Use Animal Welfare

Suppliers Investors Combatting Modern Slavery and Human Trafficking Statement Events and Webinars Careers Site Map